To conclude, the evidence is inconclusive concerning thiazolidinediones’ role in treating NSCLC and more studies are imperative to determine the downstream effectors of PPAR-γ that mediate the antitumorigenic effects in NSCLC. This evidence concerns the gene PPARG and non-small cell lung carcinoma.